The Clinical Core has characterized, followed and provided subjects and data, and has collected and banked biological specimens that have contributed to much research progress in the past 25 years in areas such as early and accurate diagnosis of AD, tracking the course of dementia, and testing new treatment approaches for AD.
The Specific Aims are: (1) Maintain and follow a panel of 400 well characterized English-speaking subjects with Alzheimer's disease (AD), dementia with Lewy bodies (DLB), Parkinson's Disease with Dementia (FDD), Mild Cognitive Impairment (MCI), and age- and education-matched healthy control subjects. (2) Maintain and follow a panel of 100 well characterized Spanish and English-speaking Hispanic subjects with Alzheimer's disease (AD), dementia with Lewy bodies (DLB), Parkinson's Disease with Dementia (PDD), Mild Cognitive Impairment (MCI), and age- and education-matched healthy control subjects through our Hispanic Initiative. (3) Maintain a high autopsy rate (i.e., greater than 70%). (4) Perform annual detailed and standardized nursing, neurological, and neuropsychological evaluations of all subjects. (5) Maintain and augment banks of plasma, DNA, and CSF from subjects with AD, MCI, and healthy controls. (6) Share clinical data with the National Alzheimer's Disease Data Coordinating Center (NACC) Uniform Data Set (UDS) and with investigators performing other multi-center analyses of clinical data. (7) Participate in projects with other ADCs (e.g., NACC), in ADNI, and in multi-center therapeutic drug trials for AD. (8) Refine and evaluate clinical and neuropsychological assessment procedures for accurate identification of MCI and the transition to AD in very mildly impaired subjects. (9) Refine and evaluate clinical, neuropsychological, and laboratory assessment procedures for the accurate differentiation of AD from DLB, PDD, Frontotemporal dementia (FTD), and other dementing disorders. (10) Coordinate activities such as autopsy procurement and education with other Cores.

Public Health Relevance

AD affects millions of Americans with its risk growing exponentially with age. The AD Centers Program fosters research related to AD and non-AD dementias. The ADRC will enhance the performance of innovative research on AD and related topics, including research that may lead to potential disease modifying therapies or behavioral treatments. It will provide an environment and core resources to enhance research, foster professional and community training, and coordinate interdisciplinary research.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005131-29
Application #
8375261
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
29
Fiscal Year
2012
Total Cost
$949,325
Indirect Cost
$210,576
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600
Chen, Xu-Qiao; Fang, Fang; Florio, Jazmin B et al. (2018) T-complex protein 1-ring complex enhances retrograde axonal transport by modulating tau phosphorylation. Traffic 19:840-853
Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71
Zhou, Zilu; Wang, Weixin; Wang, Li-San et al. (2018) Integrative DNA copy number detection and genotyping from sequencing and array-based platforms. Bioinformatics 34:2349-2355
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358
Sundermann, Erin E; Tran, My; Maki, Pauline M et al. (2018) Sex differences in the association between apolipoprotein E ?4 allele and Alzheimer's disease markers. Alzheimers Dement (Amst) 10:438-447
Edmonds, Emily C; Weigand, Alexandra J; Thomas, Kelsey R et al. (2018) Increasing Inaccuracy of Self-Reported Subjective Cognitive Complaints Over 24 Months in Empirically Derived Subtypes of Mild Cognitive Impairment. J Int Neuropsychol Soc 24:842-853
Graves, Lisa V; Van Etten, Emily J; Holden, Heather M et al. (2018) Refining CVLT-II recognition discriminability indices to enhance the characterization of recognition memory changes in healthy aging. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 25:767-782

Showing the most recent 10 out of 914 publications